Director/PDMR Shareholding

RNS Number : 7830K

GlaxoSmithKline PLC

24 December 2008

 



This announcement replaces the original announcements released on 6 May 2008 at 16.30 (RNS No: 8168T); 4 August 2008 at 18.11 (RNS No: 6189A); and 7 November 2008 at 18.02 (RNS No: 7658H).

The Administrators of the GlaxoSmithKline Performance Share Plan (the "Plan") notified the Company on 8 December 2008 of a correction to the market price of Ordinary shares used to calculate the number of shares reinvested under the dividend reinvestment element of the Plan for participants who both received Ordinary shares and who were detailed in the affected original announcements, in respect of dividends paid to shareholders on 10 July 2008. The market price of Ordinary shares should have read £11.21 (rather than £11.20), and the participants' increased interests in Ordinary shares have been corrected.

Given the cumulative nature of dividend reinvestment, the correction in respect of the payment made on 10 July 2008 also had a minor impact on the calculation of the dividends reinvested for the affected Plan participants in respect of the payments made on 9 October 2008 and 8 January 2009.

Details in respect of JP Garnier, C Viehbacher and SM Werner are excluded from these replacements as JP Garnier and C Viehbacher are no longer directors of the Company, and SM Werner is no longer deemed a Person Discharging Managerial Responsibility.

Save as disclosed above, all other details remain unchanged.

Notification of Transactions of Directors, Persons Discharging 

Managerial Responsibility or Connected Persons

The administrators of the GlaxoSmithKline Performance Share Plan (the "Administrators") notified the Company and the under-mentioned persons on 6 May 2008 of an increase in their notional interests in Ordinary shares at a price of £11.21 per share and Ordinary Share ADRs at a price of $44.11 per ADR following the notional re-investment of the dividend paid to shareholders on 10 July 2008.

	Ordinary shares	ADRs
Mr A P Witty	4,600.76
Mr J S Heslop	3,738.77
Dr M M Slaoui	332.61	1,657.54
Mrs C E Bruck Slaoui	26.51	37.72
Mr J M Clarke	2,787.62
Mr M Dunoyer	1,049.88
Mr E J Gray	870.19
Mr R G Greig		917.26
Mr D Learmouth	573.25
Mr W C Louv		666.68
Mr D J Phelan		1,412.58
Dr D Pulman		917.26

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a). 

S M Bicknell

Company Secretary

6 May 2008

  Notification of Transactions of Directors, Persons Discharging 

Managerial Responsibility or Connected Persons

The administrators of the GlaxoSmithKline Performance Share Plan (the "Administrators") notified the Company and the under-mentioned persons on 4 August 2008 of an increase in their notional interests in Ordinary shares at a price of £11.67 per share and Ordinary Share ADRs at a price of $46.53 per ADR following the notional re-investment of the dividend paid to shareholders on 9 October 2008.

	Ordinary shares	ADRs
Mr A P Witty	5,161.32
Mr J S Heslop	3,633.05
Dr M M Slaoui	323.20	1,591.48
Mrs C E Bruck Slaoui	25.76	36.21
Mr S M Bicknell	272.17
Mr J M Clarke	2,708.79
Mr M Dunoyer	1,020.19
Mr E J Gray	845.58
Mr S A Hussain	500.36
Mr D Learmouth	557.04
Mr W C Louv		640.11
Mr D J Phelan		1,356.28
Dr D Pulman		880.70
Mr D S Redfern	415.11
Mr J R Stéphenne	935.76
Ms C Thomas	312.39

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a). 

S M Bicknell

Company Secretary

4 August 2008

  Notification of Transactions of Directors, Persons Discharging

Managerial Responsibility or Connected Persons

The administrators of the GlaxoSmithKline Performance Share Plan (the "Administrators") notified the Company and the under-mentioned persons on 7 November 2008 of an increase in their notional interests in Ordinary shares at a price of £11.66 per share and Ordinary Share ADRs at a price of $37.32 per ADR following the notional re-investment of the dividend to be paid to shareholders on 8 January 2009.

	Ordinary shares	ADRs
Mr A P Witty	5,625.08
Mr J S Heslop	3,959.49
Dr M M Slaoui	352.24	1,835.07
Mrs C E Bruck Slaoui	28.07	41.75
Mr S M Bicknell	296.63
Mr J M Clarke	2,952.18
Mr M Dunoyer	1,111.86
Mr E J Gray	921.56
Mr S A Hussain	545.32
Mr D Learmouth	607.09
Mr W C Louv		738.09
Mr D J Phelan		1,563.87
Dr D Pulman		1015.50
Mr D S Redfern	452.41
Mr J R Stéphenne	1,019.84
Ms C Thomas	340.46

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a). 

Victoria A Whyte

Deputy Company Secretary

7 November 2008

---

 

END

 

 

RDSLZLFLVLBFFBF